Drug Trial Radar · NCT01236144
A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.
Last checked: Nov 20, 2026Latest source record: Jun 11, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
113
Actual
Start
Apr 2011
Primary completion
Dec 2013
Study completion Jan 2014
Sponsor
- Lead sponsor
- Cardiff UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Leukaemia & Lymphoma Research Group; Experimental Cancer Medicine Centres
- First posted
- Nov 8, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The AML18 Pilot Trial will evaluate the feasibility of three interventions that are planned to be included in the forthcoming NCRI AML18 Trial. One intervention will be to evaluate combining the Tyrosine Kinase Inhibitor AC220 with three courses of standard DAE (Daunorubicin, Ara-C, Etoposide). AC220 will be given following each treatment course, daily by mouth for 7, 14 or 21 days. AC220 will be evaluated at 3 dose levels of 60, 90 and 135 mg flat dose. A 4th dose level of 40 mg will be introduced should patients not respond well to 60 mg. The second intervention to be tested is the combination of the CXCR4 inhibitor Plerixafor with up to three courses of the chemotherapy combination of DClo (Daunorubicin, Clofarabine). Patients/investigators will be able to choose which intervention to enter. Depending on recruitment requirements, only one intervention might be available at any one time. The third intervention Patients will receive 3 treatments of 100 mg of ganetespib on days 1, 8 and 15 of each course where day 1 is the first day of the chemotherapy. The chemotherapy will be DAE/DAE/DA. Three courses of chemotherapy will be given each of which will be associated with 3 administrations of ganetespib.
Conditions
- Acute Myeloid Leukaemia
- High Risk Myelodysplastic Syndrome
Interventions
PlerixaforDrug
Fixed dose of Plerixafor (240mcg/kg) given by subcutaneous injection on each day of chemotherapy for up to 3 courses (depending on cohort). The three chemotherapy courses will be Daunorubicin/Clofarabine for courses 1\&2 and Daunorubicin/Ara-C for course 3. Each course will last 5 days, and Plerixafor will be given for 5 days.
AC220Drug
Each cohort of patients will receive three courses of chemotherapy approximately 4 to 5 weeks apart which will comprise of Daunorubicin/Ara-C/Etoposide in Courses 1\&2 and Daunorubicin/Ara-C in Course 3. Two days after the last day of each chemotherapy course, patients will receive AC220 orally for 7, 14 or 21 (depending on cohort) consecutive days. Depending on which cohort the patient enters, they will receive either 60mg, 90mg or 135mg of AC220 daily, with a provision to assess 40mg if necessary.
GanetespibDrug
Patients will receive 3 treatments of ganetespib on days 1, 8 and 15 of each course where day 1 is the first day of the chemotherapy. The chemotherapy will be DAE/DAE/DA. Three courses of chemotherapy will be given each of which will be associated with 3 administrations of ganetespib.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response (CR, CRi, PR) achievement, and reasons for failureTime frame: Duration of treatment
- MortalityTime frame: At 30 days and 8 weeks
- Toxicity (haematological and non-haematological)Time frame: Duration of trial treatment
- SurvivalTime frame: At 6 and 12 months
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Aberdeen Royal Infirmary
Aberdeen, United Kingdom
Belfast City Hospital
Belfast, United Kingdom
Birmingham Heartlands Hospital
Birmingham, United Kingdom
Addenbrooke's Hospital
Cambridge, United Kingdom
University Hospital of Wales
Cardiff, United Kingdom
Castle Hill Hospital
Hull, United Kingdom
St James's University Hospital
Leeds, United Kingdom
Royal Liverpool University Hospital
Liverpool, United Kingdom
St Bartholomew's Hospital
London, United Kingdom
Christie Hospital
Manchester, United Kingdom
Manchester Royal Infirmary
Manchester, United Kingdom
Freeman Hospital
Newcastle, United Kingdom
Nottingham University Hospital
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.